Skip to main content

Weather Alert

Hurricane activity is severely impacting Quest locations across the Southeast. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational.

Hide

KRAS G12C Mutation: An Emerging Biomarker for NSCLC

Educational objectives:

 

  -  Review the evolving NSCLC biomarker landscape, demographics

      and histopathology

  -  Raise awareness that KRAS G12C is the most prevalent emerging

      molecular target in NSCLC

  -  Discuss the available methods and clinical guideline

      recommendations for biomarker testing at diagnosis of NSCLC

 

Presented by:

 

Fesko, Yuri, MD, Chief Clinical Officer, Oncology Quest Diagnostics, Secaucus, New Jersey

 

Hooper, Kari, MD; Pathologist, AmeriPath®/Quest Diagnostics; Department Chair, Integris Baptist Medical Center Oklahoma City, Oklahoma

Date:
Jan 04, 2021
Presenter(s):
Kari Hooper, and Yuri Fesko